Please assess the completion status of the following clinical trial:

Trial Title: A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Participants With Chronic Kidney Disease.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* chronic kidney disease, stage 3 or 4;~* anemia (baseline hemoglobin between 9 and 11 grams per deciliter \[g/dL\]).~Exclusion Criteria:~* previous therapy with ESA within 12 weeks prior to screening;~* significant acute or chronic bleeding such as overt gastrointestinal bleeding;~* red blood cell transfusions within 8 weeks before screening;~* active malignant disease (except non-melanoma skin cancer).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methoxy Polyethylene Glycol-epoetin Beta (Type: EXPERIMENTAL): Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose will be 1.2 micrograms per kilogram (mcg/kg) body weight. Thereafter, throughout the duration of study the dose adjustments will be performed depending on the hemoglobin value.

Based on this trial design, predict the completion outcome and termination type (if applicable).